game changing PoC screening device to be used at the front line in the fight against Corona.

The rapid spread of the Corona virus leads to a need for reliable Point of Care (PoC) tools offering rapid screening for the virus.

Corona spreads via small droplets, aerosols, being released in coughs, sneezes or simply in the exhaled breath, and scientific evidence exists to support the accurate detection of virus by Exhaled Breath Condensate (EBC).

We intend to expand on an existing technology, the Inflammacheck(r), to test for Corona in EBC. The Inflammacheck(r) is a handheld, non-invasive, Point-of-Care (PoC) device which detects hydrogen peroxide (H2O2) in EBC, a well-documented biomarker for inflammatory conditions in the airways system. The full test cycle including sample collection and test assay typically takes place in 5 minutes following a fully automated procedure.

The Inflammacheck(r) is CE marked and registered with the MHRA for sales and use in the UK as well as in the EU by September 2019\.

We aim to deploy a Corona specific sensor within the framework of the Inflammacheck to establish an easy-to-use, rapid and reliable screening device for Corona.

Following proof-of-concept through a feasibility study, we intend to partner up with a suitable partner to drive scale up and commercialisation of the concept.

To reduce time to market, we intend to initiate planning for scale up, additional clinical trials, and regulatory handling immediately after having obtained proof-of-concept; that is, even before having a partner agreement in place and having agreed on partner funding.